Status:
COMPLETED
Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal
Lead Sponsor:
Institute of medicine, Maharagjung medical campus
Conditions:
Epistaxis
Eligibility:
All Genders
40+ years
Brief Summary
This study aims to determine the prevalence of epistaxis and identify the associated risk factors among patients receiving oral anticoagulants and antiplatelet at a tertiary care hospital in Nepal. A...
Detailed Description
Study Design and duration This study employed a hospital-based observational, cross-sectional design to determine the prevalence of epistaxis and identify the associated factors among patients on oral...
Eligibility Criteria
Inclusion
- The study included individuals aged 40 years or older who had been prescribed oral anticoagulants or antiplatelet agents for at least 3 months.
Exclusion
- Patients were excluded if they had a known bleeding disorder unrelated to the use of anticoagulant or antiplatelet medication, a history of coagulopathy or other bleeding disorders (e.g., hemophilia), recent craniofacial or nasal trauma or surgery within the past 6 months, a known history of nasal polyps or other nasal lesions, or if they declined to provide consent.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 10 2024
Estimated Enrollment :
284 Patients enrolled
Trial Details
Trial ID
NCT06906861
Start Date
November 1 2023
End Date
November 10 2024
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IOM
Kathmandu, Bagmati, Nepal, +977